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ABSTRACT
Introduction: Target organ damage (TOD) is associated
with increased cardiovascular risk. The study objectives
were to analyse the relationship of TOD to blood
pressure, size of retinal arteries and veins, oxidative
stress and different polymorphisms in the VAV-2 and
VAV-3 genes in participants with hypertension.
Methods and analysis: A case–control study to
analyse the relationship between clinical, biochemical and
genetic parameters and presence of cardiac, vascular and
renal TOD in 486 patients with hypertension. Participants
with TOD will be considered as cases, and those without
TOD will be enrolled as controls. This will be a
collaborative study conducted by the groups of Primary
Care, Cardiovascular and Metabolic and Degenerative
Diseases of the Instituto de Investigación Biomédica of
Salamanca (IBSAL). Assessment of cardiac, renal and
vascular TOD. Measurement of peripheral and central
blood pressure, size of eye fundus arteries and veins, and
oxidative stress, and polymorphisms in the VAV-2 and
VAV-3 genes.
Ethics and dissemination: The study will be
conducted after approval is obtained from the Ethics
Committee of Hospital Clínico Universitario of
Salamanca. All study participants will sign an informed
consent to agree to participate in the study, and another
consent to agree on the genetic study, in compliance
with the Declaration of Helsinki and the WHO standards
for observational studies. The results of this study will
allow for an understanding of the relationship of the
different TODs with blood pressure, retinal artery and
vein diameters, oxidative stress and polymorphisms in
VAV-2 and VAV-3 genes.
Trial registration number: Clinical Trials. gov
Identifier: NCT02022618.
INTRODUCTION
The relationship of blood pressure (BP) of
morbidity and mortality from coronary artery
diseases, heart failure and renal failure is
increasing and continuous.1 Cardiovascular
(CV) risk in participants with hypertension is
inﬂuenced by BP levels, presence of CV risk
factors, target organ damage (TOD) and clin-
ically established CV disease (CVD), accord-
ing to the 2013 guidelines of the European
Society of Hypertension and the Europeran
Society of Cardiology (ESG-ESC).2
Presence of cardiac,3 4 renal5 6 and vascu-
lar7–10 TOD is considered as a surrogate
variable and is associated with increased
CV risk.
Ambulatory BP (ambulatory blood pressure
monitoring (ABPM) and home blood pressure
(HABP)) predict CV morbidity and mortality
better than does ofﬁce BP11–14 and are
associated with the presence of TOD.15–17
ABPM parameters allow for estimating the
ambulatory arterial stiffness index (AASI),
which is related to morbidity and mortality for
CVD18 19 and the presence of TOD in patients
with hypertension.3–8 AASI may be helpful to
assess arterial stiffness20 21 and correlates to
other classical measurements such as pulse
wave velocity (PWV).21
ABPM also allows for assessing 24 h variabil-
ity in BP.22 Thus, participants with a lower
nocturnal decrease in BP have a poorer
course23 and a higher prevalence of TOD.20
Central BP is a determinant factor in myo-
cardial perfusion and cardiac work. This par-
ameter is associated with CV morbidity and
mortality9 24 and with intermediate markers
such as left ventricular hypertrophy (LVH),25
carotid intima-media thickness (IMT),26 cor-
onary atherosclerosis27 or decreased glomeru-
lar ﬁltration rate.26 Central haemodynamic
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indices are independent predictors of future CV events
and all-cause mortality.28 There is sufﬁcient evidence to
show that increased pulse-wave reﬂection predicts CV mor-
tality independently of arterial stiffness in men and
women.29
An eye fundus examination allows for non-invasive
assessment of retinal microcirculation. The classical
Keith-Wagener classiﬁcation has limitations for analysis of
retinal vascular lesions, particularly for adequate assess-
ment of early vascular lesions. Different tools to quantita-
tively assess artery size have been developed,30–33 but all
of them require the intervention of an observer.
Population studies have found that retinal vessel calibre is
related to risk of hypertension,34 LVH,35 cerebrovascular
accidents36 and coronary artery disease.37 A meta-analysis
of six population studies showed that retinal vessel calibre
was associated with increased risk of coronary disease in
women, but not in men.38 However, conﬂicting results
have been reported with regard to the course of athero-
sclerotic lesions and retinal vessel calibre.39–41 Cuspidi
et al42 and Masaidi et al43 found no association between
retinal vessel calibre and TOD (cardiac, vacular, renal) in
a population with hypertension. This study will use a
semiautomated tool developed by our AV group Index cal-
culator (Ciclorisk SL, Salamanca, Spain, registry no. 00/
2011/589), recently validated44 and highly reliable, to
analyse the association of retinal artery and vein calibre
(arteriole and venule diameter and arteriovenous ratio)
with different TODs.
The oxidised form of xanthine dehydrogenase pro-
motes early endothelial dysfunction, perpetuating oxida-
tive damage in the vascular wall and myocardium
through the superoxide anion.45 Patients with hyperten-
sion experience biochemical changes showing oxidative
stress.46 When oxidative stress exists, peroxynitrite
(ONOO−), one of the reactive oxygen species with a
greater effect on the CV system, is formed. ONOO− inhi-
bits key enzymes located in the myocardium such as
ATPase Ca2+47 and creatine kinase,48 activates metallo-
proteinases49 and modulates signalling systems of
mitogen-activated protein kinases50 and nuclear tran-
scription factor EB,51 as well as activating the enzyme
poly (ADP-ribose) polymerase.52 According to Levrand
et al,52 ONOO− may be involved in apoptotic events con-
tributing to cell loss in the myocardum.
Essential hypertension is a highly heterogeneous dis-
order with a multifactorial aetiology.2 Several genome-
wide association studies and their meta-analyses point to
a total of 29 single nucleotide polymorphisms, which are
associated with systolic BP (SBP) and/or diastolic BP
(DBP).53 These ﬁndings may be useful contributors to
risk scores for TOD.2 The VAV gene is very widely
expressed, and its distribution is virtually universal.54 In
the VAV family, a direct relationship exists between recep-
tors with intrinsic activity or with activity associated with
tyrosine kinase and pathways regulating mitogenesis and
the cytoskeleton through nucleotide exchange in Rho/
Rac proteins.54 Sauzeau et al55 assessed in knockout mice
the consequences of VAV-2−/− at the vascular and
cardiac level and on other elements of CV homeostasis.
At the vascular level, they found extensive remodelling in
the whole CV system, except in pulmonary circulation,
and changes in the media layer of the aortic wall. In the
heart, they found LVH with ﬁbrosis, with no right ven-
tricle involvement. In the kidney, these authors found
interstitial ﬁbrosis, decreases in glomerular ﬁltration,
sodium excretion and creatinine clearance and increased
aldosterone and vasopressin levels associated with
changes in the renin-angiotensin-aldosterone system and
endothelin. Elevated epinephrine and norepinephrine
levels, and normal dopamine levels, were also found. All
these ﬁndings allow for stating that VAV-2−/− mice have
CV impairment, and for deﬁning part of the pathophysio-
logical substrate underlying such impairment. The same
research team conducted a study56 in modiﬁed VAV-2−/−
mice and showed a new BP control pathway in which type
5 phosphodiesterase is involved at vascular smooth
muscle cells, causing an increased vascular tone which
was corrected with administration of phosphodiesterase
inhibitors. Genetically modiﬁed mice with VAV-3−/− 57
had elevated SBP and DBP values and tachycardia.
Administration of propranolol achieved control of BP
and tachycardia, and decreased angiotensin II levels and
cardiac remodelling. These results show a direct associ-
ation between both systems (sympathetic nervous system
and renin-angiotensin-aldosterone axis) in the develop-
ment of arterial hypertension in VAV-3−/− mice. Renal
effects were similar to those caused by VAV-2. To sum up,
experimental studies conducted in animals deﬁcient in
VAV-2 and VAV-3 show that sympathetic activation plays a
basic role in cardiac, vascular and renal changes.55 57 The
potential role of polymorphisms in these genes in BP in
humans and their association with the different TODs
have not been studied.
The study objective was to analyse the relationship of
renal, cardiac and vascular TOD with the haemodynamic
parameters of BP, retinal artery and vein calibre, urinary
excretion of oxidative stress molecules and different poly-
morphisms in the VAV-2 and VAV-3 genes in hypertensive
participants.
METHODS AND ANALYSIS
Study design
A case–control study to analyse the association between
clinical, biochemical and genetic parameters and the
presence of cardiac, vascular and renal TOD in partici-
pants with hypertension. Participants with TOD will be
considered as cases, and those without TOD will be
enrolled as controls.
Setting
This will be a collaborative study conducted by the
groups of Primary Care, CV and Metabolic and
Degenerative Diseases of the Instituto de Investigación
Biomédica de Salamanca (IBSAL). Clinical assessment
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and all examinations needed for complete evaluation of
the presence of TOD will be performed at the primary
care research unit.2 Oxidative stress testing will be per-
formed at the pathophysiology unit, and genetic poly-
morphisms will be analysed at the Unit of Molecular
Medicine of Salamanca University.
Study subjects
Consecutive participants aged 20–80 years referred to the
La Alamedilla research unit for TOD evaluation and diag-
nosed with essential hypertension will be enrolled into the
study. All participants who do not sign the written
informed consent according to general recommendations
in the Declaration of Helsinki will be excluded from the
study.58 Sample size has been estimated for detecting a
3.25% difference in the Central Augmentation Index
(CAIx), half the difference used in the CAFEE study
(6.5%), between participants with and without TOD. A 1:3
ratio between participants with and without TOD has been
considered. Considering a common SD of 10.8 units and
assuming an α risk of 0.05 and an 80% power for a two-
sided test, a total of 468 participants are required, 117 in
the ﬁrst group and 351 in the second group.
Variables and measurement instruments
CV risk factors and CVD
Risk factors
Male sex—age (men ≥55 years; women ≥65 years).
Smoking—dyslipidaemia: total cholesterol >4.9 mmol/L
(190 mg/dL) or low-density lipoprotein cholesterol
>3 mmol/L (115 mg/dL) or high-density lipoprotein
cholesterol: men <1.0 mmol/L (40 mg/dL), women
<1.2 mmol/L (46 mg/dL) or triglycerides >1.7 mmol/L
(150 mg/dL). Fasting plasma glucose 5.6–6.9 mmol/L
(102–125 mg/dL). Abnormal glucose tolerance test.
Obesity (body mass index (BMI) ≥30 kg/m2 (height2)).
Abdominal obesity (waist circumference: men ≥102 cm;
women ≥88 cm; in Caucasians). Family history of prema-
ture CVD (men aged <55 years; women aged <65 years).2
Established CV or renal disease
Cerebrovascular disease—ischaemic stroke; cerebral
hemorrhage; transient ischaemic attack coronary heart
disease: myocardial infarction; angina; myocardial revas-
cularisation. Heart failure, including heart failure with
preserved ejection fraction. Symptomatic peripheral
artery disease in lower limbs. Chronic kidney disease
(CKD) with estimated glomerular ﬁltration rate <30 mL/
min/1.73 m2 or proteinuria (>300 mg/24 h). Advanced
retinopathy: haemorrhage or exudate, papilloedema.2
Drug therapy
Antihypertensive, antidiabetic and lipid-lowering drugs
and antiplatelet treatment.
Anthropometric measurements
Body weight will be measured twice using a homolo-
gated electronic scale (Seca 770; Medical scale and
measurement systems, Birmingham, UK) after calibra-
tion (precision±0.1 kg), with the patient wearing light
clothing and was shoeless. These readings will be
rounded to 100 g. Height will be measured using a port-
able system (Seca 222; Medical scale and measurement
systems, Birmingham, UK). The mean of two readings
taken with the patient shoeless in the standing position
will be recorded. Values will be rounded to the nearest
centimetre. BMI will be calculated as weight (kg)
divided by (height)2 (m²). Waist circumference will be
measured using a ﬂexible graduated measuring tape
with the patient in the standing position without cloth-
ing. The upper border of the iliac crests will be located,
and the tape will be wrapped around above this point,
parallel to the ﬂoor, ensuring that it is adjusted but
without compressing the skin.
Blood pressure
Ofﬁce or clinical BP—ofﬁce BP will be determined by
three measurements of SBP and DBP, using the mean of
the last two values, with a validated OMRON model
M10-IT sphygmomanometer (Omron Health Care,
Kyoto, Japan), according to the recommendations of the
European Society of Hypertension.59 Pulse pressure will
be estimated using the mean values of the second and
third measurements.
Home BP—This parameter will be measured using an
OMRON model M10-IT sphygmomanometer (Omron
Health Care, Kyoto, Japan). Three measurements will be
made in the morning (between 6:00 and 9:00), and
three in the afternoon/evening (between 18:00 and
21:00), over a period of 7 days, with a minimum interval
of 1 min between measurements, and excluding the ﬁrst
measurement in each case and the values corresponding
to the ﬁrst day of measurement.60 The investigator will
train patients on BP measurement at home. Written
instructions and a self-recording sheet will be provided
to ensure adequate pressure monitoring.
Ambulatory BP monitoring
The monitoring will be performed on a day of standard
activity using an adequate cuff for the size of the
patient’s arm. A control system, SpaceLabs 90207 model
(Spacelabs Healthcare, Issaquah, Washington, USA),
validated according to the protocol of the British
Hypertension Society, will be used.61 Valid registries will
be required to meet a number of pre-established cri-
teria, including ≥80% successful SBP and DBP record-
ings during the daytime and night-time periods, 24 h
duration and ≥1 BP measurement/h. The monitor will
be scheduled to obtain BP measurements every 15 min
during the daytime and night-time periods. Patients will
be categorised based on the circadian pattern, which
will be estimated by the sleep to wake ratio of SBP, as
dipper, <0.9; non-dipper, 0.9–1; and riser, >1. The noc-
turnal dip will be deﬁned as the difference between the
mean waking BP and the mean sleeping BP expressed as
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a percentage (systolic dip %=100×(mean SBP day−mean
SBP night)/mean SBP day).
AASI and (HASI)
Arterial stiffness will be evaluated based on the AASI
and home arterial stiffness index (HASI). To estimate
AASI and HASI, the regression slope of diastolic on SBP
will be computed for each participant based on 24 h
ABPM (AASI) and on HASI readings over 6 days. Both
AASI and HASI were deﬁned as one minus the respect-
ive regression slope of DBP on SBP.62 AASI will also be
computed from waking or sleeping BP.
Evaluation of retinal vessels
Retinography will be performed using a Topcon TRC
NW 200 non-mydriatic retinal camera (Topcon Europe
B.C., Capelle a/d Ijssel, The Netherlands), obtaining
nasal and temporal images centred on the disk. The
nasal image with the centred disk will be loaded into the
developed software, AV Index calculator (Ciclorisk SL,
Salamanca, Spain, registry no. 00/2011/589). This soft-
ware automatically recognises the disk and draws two
external concentric circles which delimit area A, 0–0.5
disk diameters from the optic disk margin, and area B,
0.5–1 disk diameters from the margin. The software ﬁrst
identiﬁes the limits of the different vessels, after which it
automatically recognises arteries and veins, and makes
multiple measurements of the diameter of the section of
vessels circulating through area B. It ﬁnally estimates the
mean calibre of veins and arteries in millimetres, and
these measurements are summarised as an arteriole–
venule ratio, arteriovenous index (AVIx). An AVIx of 1.0
suggests that arteriolar diameters are on average the
same as venular diameters in that eye, whereas a smaller
AVR suggests narrower arterioles. The pairs of main
vessels in the upper and lower temporal quadrants will
be used, rejecting all other vessels, to improve reliability
and increase efﬁciency of the process, analysing mea-
sures for each quadrant separately and together to esti-
mate the mean measure in each eye.
Target organ damage
Renal assessment
Kidney damage will be assessed by measuring the esti-
mated glomerular ﬁltration rate using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI)63 equa-
tion and proteinuria, as assessed by the albumin/creatin-
ine ratio following the criteria of the 2013 European
Society of Hypertension/European Society of Cardiology
Guidelines.2 Subclinical organ damage will be deﬁned as a
glomerular ﬁltration rate below 30–60 mL/min/1.73 m2
or microalbuminuria (30–300 mg/24 h) or albumin–cre-
atinine ratio (30–300 mg/g; 3.4–34 mg/mmol) (prefer-
ably on morning spot urine). Renal disease will be deﬁned
as a glomerular ﬁltration rate <30 mL/min/1.73 m2
(BSA), proteinuria (>300 mg/24 h) or albumin/creatin-
ine ratio >300 mg/24 h.2
Cardiac assessment
ECG examination will be performed using a General
Electric MAC 3.500 ECG System (Niskayuna, New York,
USA) that automatically measures wave voltage and dur-
ation and estimates the criteria of the Cornell voltage-
duration product (VDP).64 ECG LVH will be deﬁned as
a Sokolow-Lyon index >3.5 mV; RaVL >1.1 mV, Cornell
VDP >244 mV*ms or RaVL >1.1 mV.2
PWV and CAIx
These parameters will be estimated using the
SphygmoCor System (AtCor Medical Pty Ltd, Head
Ofﬁce, West Ryde, Australia). With the patient sitting
and resting his/her arm on a rigid surface, pulse wave
analysis will be performed with a sensor in the radial
artery, using mathematical transformation to estimate
the aortic pulse wave and CAIx. CAIx will be estimated
from aortic wave morphology using the following
formula: increase in central pressure×100/pulse pres-
sure. Carotid and femoral artery pulse waves will be ana-
lysed, with the patient in a supine position, using the
SphygmoCor System (Vx PWV), estimating the delay as
compared to the ECG wave and calculating PWV.
Distance measurements will be taken with a measuring
tape from the sternal notch to the carotid and femoral
arteries at the sensor location. Subclinical organ damage
will be deﬁned as a carotid–femoral PWV >10 m/s.2 65
Assessment of vascular structure using carotid IMT
Carotid ultrasound to assess C-IMT will be performed by
two investigators trained for this purpose before study
start. A Sonosite Micromax ultrasound device paired with
a 5–10 MHz multifrequency high-resolution linear trans-
ducer with Sonocal software will be used for performing
automated measurements of carotid IMT in order to
optimise reproducibility. Measurements will be made of
the common carotid after examination of a 10 mm longi-
tudinal section at a distance of 1 cm from the bifurcation.
Measurements will be taken in the proximal wall, and in
the distal wall in the lateral, anterior and posterior projec-
tions, following an axis perpendicular to the artery to dis-
criminate two lines: one for the intima-blood interface
and the other for the media-adventitious interface.
A total of six measurements will be taken of both the
right carotid and left carotid arteries, using average
values (average carotid IMT) and maximum values
(maximum carotid IMT) automatically calculated by the
software.66 Measurements will be taken with the partici-
pant lying down, with the head extended and slightly
turned opposite to the examined carotid artery. Average
IMT will be considered abnormal if >0.90 mm or if there
are atherosclerotic plaques with a diameter of 1.5 mm or
a focal increase of 0.5 mm or 50% of the adjacent IMT.2
Evaluation of peripheral artery involvement
This will be assessed using the ankle-brachial index, cal-
culated in the morning in patients who have not drunk
coffee or smoked tobacco for at least 8 h before
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measurement and at a room temperature of 22–24°C.
With the patient lying in a supine position and with the
feet uncovered, pressure in the lower limbs will be mea-
sured after resting for 20 min using a portable WatchBP
Ofﬁce for assessing the ankle–brachial index (Microlife
AG Swiss Corporation Espenstrasse 139. CH-9443
Widnau/Switzerland). The ankle–brachial index will be
calculated automatically for each foot by dividing the
higher of the two systolic pressures in the ankle by the
higher of the two systolic pressures in the arm. An
ankle–brachial index <0.9 will be considered abnormal.2
Laboratory measurements
Venous blood sampling will be performed between 8:00
and 9:00 after participants have fasted and abstained from
smoking and consumption of alcohol and caffeinated bev-
erages for 12 h. Fasting plasma glucose, creatinine, uric
acid, serum total cholesterol, high-density lipoprotein
cholesterol and triglyceride levels will be measured using
standard enzymatic automated methods. Low-density lipo-
protein cholesterol will be estimated by the Friedewald
equation when the direct parameter is not available.
Glycated haemoglobin will be measured using an immune
turbidimetric assay. High-sensitive C reactive protein and
ﬁbrinogen levels will be measured by an immune turbidi-
metric assay. Insulin blood levels will be measured using a
chemiluminescent microparticle immunoassay. Insulin
sensitivity will be determined with the Homeostasis Model
Assessment Insulin Resistance (HOMA-IR) index67 using
the following formula: fasting glucose (mmol/L)×fasting
insulin (mU/mL)/22.5.
Superoxide anion and catecholamine (epinephrine and
norepinephrine) levels in plasma and urine will be mea-
sured using ELISA (CatCombi ELISA, IBL, Deventer, The
Netherlands) following the manufacturer’’s instructions.
Superoxide dismutase activity in plasma will be assessed
using ELISA kits (Cu-Zn Superoxid-dismutase ELISA,
IBL), and lipid peroxide plasma levels and urinary excre-
tion by measuring thiobarbituric acid reactive substances
(TBARS; OxiSelect TBARS Assay Kit, Cell Biolabs, Inc, San
Diego, California, USA).
Polymorphisms in the VAV-2 and VAV-3 genes will be
tested in all study participants in a DNA sample from
peripheral blood erythrocytes. For this purpose, 10 mL
of venous blood anticoagulated with EDTA will be taken.
People who perform the different tests will be blinded
to the clinical patient data. All organ damage assess-
ments will be made within 10 days.
Statistical analysis
Normal distribution of variables will be veriﬁed using a
Kolmogorov-Smirnov test. Quantitative variables will be
displayed as the mean±SD if normally distributed or as
the median (IQR) if asymmetrically distributed, and
qualitative variables will be expressed as frequencies.
Analysis of difference of means between variables of two
categories will be carried out using a Student’ t test or a
Mann-Whitney U test, as appropriate, while qualitative
variables will be analysed using a χ² test. To analyse the
relationship between qualitative variables of more than
two categories and quantitative variables, an analysis of
variance and the least signiﬁcant difference test will be
used in the post hoc tests. The relationship of quantita-
tive variables to each other will be tested using
Pearson’’s or Spearman’’s correlation as appropriate. A
multivariate analysis of variance will be performed with
analysis of covariance and multivariate analysis of vari-
ance to adjust results for potentially confounding vari-
ables. Logistic regression will be used to analyse clinical,
biochemical and genetic variables associated with the
presence of cardiac, vascular and renal TOD. IBM
SPSS/PC + statistical software V.20.0 will be used. Data
will be computed using a Teleform system in a question-
naire previously designed for the project and exporting
data to SPSS software for subsequent analysis.
Quality control
Different processes will be carried out to guarantee study
data quality and thus maximise the validity and reliability
of measurements of the results. To this effect, ﬁeld work
operation manuals have been prepared which specify the
adequate procedure for performing each test. Educational
leaﬂets will be developed to ensure adequate pressure
measurement by patients at home. All of these actions will
conﬁrm adequate performance of each procedure.
Monthly meetings will be held with the principal investiga-
tor of the study to analyse the entire process, and an
annual report on study progress will be prepared.
Ethical and legal issues
All study participants will sign an informed consent to
agree to participate in the study, and another consent to
agree on the genetic study, in compliance with the
Declaration of Helsinki58 and the WHO standards for
observational studies. The study will involve collection
and storage of biological samples, and study participants
will therefore be thoroughly informed. Sample traceabil-
ity will be maintained until study completion, after
which samples will be irreversibly dissociated from per-
sonal data or destroyed, as decided by the study partici-
pant. Owing to the foregoing, conﬁdentiality of
participants enrolled into the study will be guaranteed at
all times in accordance with provisions in the Spanish
Organic Act on Personal Data Protection (15/1999, of
13 December, LOPD) and under the conditions set
down in Act 14/2007 on Biomedical Research.
DISCUSSION
BP measurement, both at the clinic and on an out-
patient, is a widespread clinical practice, and its direct
correlation to mortality and morbidity has been exten-
sively studied.1 However, association of 24 h ambulatory
BP, central haemodynamic parameters and AVI of retinal
vessels with presence and occurrence of TOD (renal,
cardiac and vascular) has not been collectively analysed
Gomez-Marcos MA, Gonzalez-Sarmiento R, Recio-Rodríguez J I, et al. BMJ Open 2014;4:e005112. doi:10.1136/bmjopen-2014-005112 5
Open Access
in the same group of patients. Similarly, we do not know
the relationship of TOD and all other parameters asses-
sing vascular function with oxidative stress and catechol-
amine excretion in urine. Also, it is not known if there
are certain genetic polymorphisms in the VAV-2 and
VAV-3 genes predisposing to the occurrence of TOD in
patients with hypertension.
The impact of ABPM and HABP parameters on TOD
occurrence has not been fully established, but there are
studies relating BP variability and night-time elevation to
the presence of TOD. However, we must still analyse all
other parameters and quantify the association in order to
be able to predict with greater precision the occurrence of
TOD as a function of the BP parameter evaluated.
Measurement of central BP and augmentation index is
of great interest for mechanistic analyses in pathophysi-
ology, pharmacology and therapeutics. Measurement of
central BP, as compared to brachial BP, in patients with
hypertension raises increasing interest because of its pre-
dictive value for CV events and the differential effect of
antihypertensive drugs. Arterial pressure waveform is a
composite of the forward pressure wave created by ventricu-
lar contraction and a reﬂected wave.2 It should be analysed
at the central level, that is, in the ascending aorta, because
it represents the true load imposed on the heart, brain,
kidney and large arteries. Early epidemiological studies in
the 2000s showed that CAIx and pulse pressure, directly
measured by carotid tonometry, were independent predic-
tors of all-cause and CV mortality in patients with end-stage
renal disease.2 A recent meta-analysis conﬁrmed these ﬁnd-
ings in several populations.28 However, the additive predict-
ive value of central BP beyond brachial BP was either
marginal or not statistically signiﬁcant in most studies.28
Although there is some evidence of an association
between oxidative stress and CVD, the relationship
between molecules analysing oxidative stress and TOD
occurrence is currently not known. Our group has also
shown that sympathetic activation and oxidative stress have
been found to be the basis for CV and renal damage in
other hypertension models.68 69 Similarly, there are no
studies analysing the relationship between the presence of
TOD and polymorphisms in the VAV-2 and VAV-3 genes.
To sum up, we hope that the results of this study will
contribute to a clariﬁcation of the association between
occurrence of TOD and the above discussed variables.
Study limitations
The cross-sectional design of this study may lead us to
observe an association, but not its direction over time.
There may also be confounding factors which have not
been considered. On the other hand, some patients with
hypertension are on a non-homogeneous antihyperten-
sive therapeutic regimen. Although these drugs may
have an impact on BP measurements and certain TODs,
they cannot be discontinued for ethical reasons. They
will, however, be controlled in the analysis phase. Finally,
assignment by consecutive sampling prevents generalisa-
tion of results.
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